# Cambridge Cognition strategic partnership with Luca Healthcare for Chinese market expansion

- Link: https://www.directorstalkinterviews.com/cambridge-cognition-strategic-partnership-with-luca-healthcare-for-chinese-market-expansion/4121091473
- Published: 2022-11-24T07:19:02+00:00
- Author: Giles

**Cambridge Cognition Holdings Plc** ([LON:COG](https://www.directorstalkinterviews.com/company/cambridge-cognition-holdings-plc/cog.l)),
which develops and markets digital solutions to assess brain health, has announced
an expansion in the Chinese market through a strategic partnership with Luca Healthcare
Limited, a category leader in digital screening, treatment and management tools 
in China. Cambridge Cognition has signed an exclusive licencing agreement with Luca
Healthcare to commercialise the Company’s suite of leading cognitive assessment 
tools in China for both the pharmaceutical and healthcare markets.

The strategic partnership provides Cambridge Cognition with an efficient and low
risk geographic expansion whilst leveraging the Company’s recent projects to go 
live in an Amazon Web Service (“AWS”) data centre in China and implement a range
of Chinese languages.  Cambridge Cognition will be paid through a mix of milestone
payments and royalties.  As well as a commercial license, the partnership includes
the opportunity to collaborate on co-developments to improve both companies’ solutions.

China is the second most active clinical trial market in the world after the US,
having hosted nearly 10,000 industry sponsored trials in the last five years with
14% being in Central Nervous System conditions^(1). The healthcare market opportunity
in China for cognitive impairment diagnostics may also be considerable with nearly
40 million people affected by mild cognitive impairment and nearly 10 million living
with Alzheimer’s disease^(2).

Cambridge Cognition has been laying the groundwork to successfully capitalise on
this significant market opportunity since 2019 by establishing a dedicated service
in the region delivered from a secure cloud infrastructure provided by AWS in China;
developing task variants in the most common spoken (Cantonese and Mandarin) and 
written (Chinese simplified) languages; and building on an existing relationship
with one of the leading Chinese universities, Fudan University, Shanghai.

> **Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:**
> “The Chinese pharmaceutical and healthcare markets offer a significant commercial
> opportunity for Cambridge Cognition, and we have partnered with Luca Healthcare
> to capitalise on this. The team at Luca Healthcare have impressed us with their
> speed to commercialise other digital healthcare solutions, working with leading
> pharmaceutical companies in the region and, as a result, building a fast growth
> business.”

> **Echo Chen, Chief Executive Officer of Luca Healthcare, said:**
> “We are absolutely thrilled to be working with a great team and the most validated
> cognition assessment tool in the world. Luca’s mission is to make healthcare more
> affordable and more accessible; this partnership certainly gives us an opportunity
> to do that for those impacted by neurodegenerative disorders in China.”

**References**

1.    GlobalData. Industry Sponsored Trials in China 17/11/2017 – 17/11/2022.

2.    [The China Alzheimer’s Report 2022, BMJ General Psychiatry, Vol 35-1](https://gpsych.bmj.com/content/35/1/e100751)

Share on: